Caredx issues statement on supreme court decision regarding stanford-licensed patents

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – acknowledges the supreme court's decision not to review the federal circuit's decision on the patent eligibility of three stanford-licensed patents. caredx notes the decision does not impact the company's ability to continue providing allosure® d.
CDNA Ratings Summary
CDNA Quant Ranking